An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer-Reference-Cited by-同舟云学术

An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer

Published:2018-03-23 Issue:5 Volume:7 Page:1660-1669
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Vacirca Jeffrey L.¹,Chan Arlene²,Mezei Klára³,Adoo Clarence S.⁴,Pápai Zsuzsanna⁵,McGregor Kimberly⁶,Okera Meena⁷,Horváth Zsolt⁸,Landherr László⁹,Hanslik Jerzy¹⁰,Hager Steven J.¹¹,Ibrahim Emad N.¹²,Rostom Makharadze¹³,Bhat Gajanan¹⁴,Choi Mi Rim¹⁴,Reddy Guru¹⁴,Tedesco Karen L.¹⁵,Agajanian Richy¹⁶,Láng István¹⁷,Schwartzberg Lee S.¹⁸

Affiliation:

1. New York Cancer Specialists; East Setauket New York

2. Breast Cancer Research Centre WA and Curtin University; Perth Western Australia Australia

3. Szabolcs-Szatmár Bereg County Hospital and University Teaching Hospital; Nyíregyháza Hungary

4. Arizona Center for Cancer Care; Glendale Arizona

5. State Health Center; Budapest Hungary

6. Samaritan Hematology and Oncology Associates; Corvalis Oregon

7. Adelaide Cancer Centre; Kurralta Park South Australia Australia

8. University of Debrecen; Debrecen Hungary

9. Uzsoki Hospital; Budapest Hungary

10. Szpital Rejonowy Dzienny Oddzial Chemioterapii; Raciborzu Poland

11. California Cancer Associates for Research and Excellence; Fresno California

12. Emad Ibrahim MD, Inc.; Redlands California

13. Cancer Center of Adjara Autonomous Republic; Batumi Georgia

14. Spectrum Pharmaceuticals; Irvine California

15. New York Oncology Hematology (US Oncology/McKesson Specialty Health); Albany New York

16. The Oncology Institute of Hope and Innovation; Downey California

17. National Institute of Oncology; Budapest Hungary

18. West Cancer Center; Memphis Tennessee

Funder

Spectrum Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Reference22 articles.

1. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management;Crawford;Cancer,2004

2. US Department of Health and Human Services Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 https://evs.nci.nih.gov/ ftp1/CTCAE/CTCAE

3. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours;Aapro;Eur. J. Cancer,2011

4. New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim;Ghidini;Ther. Clin. Risk Manag.,2016

5. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients;Kuderer;Cancer,2006

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy;Frontiers in Oncology;2023-01-05

2. A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects;Drugs in R&D;2022-01-06

3. Building better biobetters: From fundamentals to industrial application;Drug Discovery Today;2022-01

4. Novel G‐CSF conjugated anionic globular dendrimer: Preparation and biological activity assessment;Pharmacology Research & Perspectives;2021-07-16

5. Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review;Critical Reviews in Oncology/Hematology;2021-01